Monitor the stock's bid price over the coming weeks. Any reverse stock split or other curative action by management would be a key event. Failure to regain compliance by May 2027 could lead to delisting and loss of Nasdaq listing.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $0.1575entry
- T+1 · 11d ago −44.13%α −44.44% · $0.0880
- T+5 · 5d ago −31.87%α −35.16% · $0.1073
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Baird Medical received a Nasdaq deficiency notice for failing to maintain the minimum $1.00 bid price for 30 consecutive business days. The company has a 180-day compliance period until May 3, 2027, to regain compliance, and its shares continue to trade uninterrupted. With a market cap of only $6M, the delisting risk is material if the bid price is not cured.
Key Facts
- Nasdaq notified Baird Medical on November 2, 2026 of non-compliance with minimum $1.00 bid price rule (Listing Rule 5550(a)(2)).
- Company has 180 calendar days, until May 3, 2027, to regain compliance by having a closing bid price of $1.00 or above for 10 consecutive business days.
- If not cured, the company may be eligible for an additional 180-day grace period or face delisting.
- Market cap is approximately $6M, making delisting a potentially existential risk.
Financial Impact
No direct financial impact stated; delisting risk if bid price not cured by May 2027.
Risk Factors
- Potential delisting if bid price remains below $1.00 after compliance period(s).
- Low market cap ($6M) limits financing and strategic options to cure deficiency.
- Forward-looking statements about business expansion and regulatory conditions carry uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395779 |
Track record
9 reports on BDMD
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +91.10% at T+60 after the Aug 18, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bearish 6/10 Entry $0.0910 Now $0.1070 −17.58% settles Dec 16
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $0.1073 Now $0.1070 −0.28% settles Dec 11
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $0.1575 Now $0.1070 +32.06% settles Dec 4
- Nov 4, 202612d ago Press Release Bearish 6/10 Viewing Entry $0.1575 Now $0.1070 +32.06% settles Dec 4
- Sep 30, 20266w ago 6-K Bearish 6/10 Entry $0.7440 to $0.1833 Now $0.1070 +85.62% ▲ +75.36% +76.07% vs SPY
- Sep 30, 20266w ago 6-K Mixed 6/10 Entry $0.7800 to $0.2820 Now $0.1070 −86.28% ▼ −63.85% −65.12% vs SPY
- Sep 3, 202610w ago 6-K Bullish 6/10 Entry $1.17 to $0.7511 Now $0.1070 −90.85% ▼ −35.80% −34.62% vs SPY
- Sep 3, 202610w ago Press Release Bullish 6/10 Entry $1.17 to $0.7511 Now $0.1070 −90.85% ▼ −35.80% −34.62% vs SPY
- Aug 18, 202613w ago EFFECT Bearish 6/10 Entry $1.09 to $1.06 Now $0.1070 +90.18% ▲ +2.75% +1.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers